A notable advancement in diabetes care is emerging with the approval of tirzepatide in a 45mg form. This updated formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, and offers a https://utherpeptidess.com/product/tirzepatide-45mg/